TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06138886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic therapy group
Description: The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic therapy group
Description: The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic therapy group
Description: The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
Study: NCT04498520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study: NCT04153383

Intervention type: DRUG
Intervention: Milrinone Injection
Description: giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
Study: NCT05599698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies
Study: NCT04498520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT05374369

Intervention type: DIAGNOSTIC_TEST
Intervention: SDC2 Gene Methylation Test and Q-FIT Test
Description: Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test

Intervention type: DIAGNOSTIC_TEST
Intervention: SDC2 Gene Methylation Test and Q-FIT Test
Description: Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
Study: NCT05998486

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG in wrist flexor-pronators and extensor-supinators
Description: The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG in wrist flexor-pronators and extensor-supinators
Description: The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
Study: NCT05102513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Cleft Lip Repair: Hybrid Technique
Description: The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Cleft Lip Repair: Millard 2 Technique
Description: A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
Study: NCT05482035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist blood pressure monitor
Description: Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
Study: NCT05374369

Intervention type: DIAGNOSTIC_TEST
Intervention: SDC2 Gene Methylation Test and Q-FIT Test
Description: Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test

Intervention type: PROCEDURE
Intervention: Colonoscopy and/or pathological examination
Description: Subjects underwent colonoscopy and/or pathological examination.
Study: NCT06027944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light exposure
Description: Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light exposure
Description: Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
Study: NCT04263779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order of Options
Description: Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Option
Description: Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
Study: NCT05374369

Intervention type: PROCEDURE
Intervention: Colonoscopy and/or pathological examination
Description: Subjects underwent colonoscopy and/or pathological examination.

Intervention type: PROCEDURE
Intervention: Colonoscopy and/or pathological examination
Description: Subjects underwent colonoscopy and/or pathological examination.
Study: NCT06157372

Intervention type: DIAGNOSTIC_TEST
Intervention: targeted next-generation sequencing (tNGS)
Description: To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: targeted next-generation sequencing (tNGS)
Description: To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
Study: NCT04859972

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of IBS
Description: Diagnosis of IBS according to ICD-10
Study: NCT05419271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home hemodialysis session with 9L internal convection
Description: home hemodialysis session with 9L internal convection
Study: NCT05064332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg by mouth (PO) Once daily (QD) for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonogestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and levonogestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Study: NCT05259930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino MP9
Description: Name used by Nualtra for their product of BCAA
Study: NCT05698043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386(5)
Description: Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386(5)
Description: Test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: Reference
Study: NCT05622344

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: Exercises that teaches subjects to move their heads while viewing still or moving targets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWAN
Description: The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWAN
Description: The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
Study: NCT04696237

Intervention type: OTHER
Intervention: Questionnaire
Description: a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed

Intervention type: OTHER
Intervention: Questionnaire
Description: a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed

Intervention type: OTHER
Intervention: Questionnaire
Description: a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
Study: NCT04967066

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Levels of Adipocytokines
Description: Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Levels of Adipocytokines
Description: Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Levels of Adipocytokines
Description: Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
Study: NCT06152406

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation and Pacemaker Implantation
Description: All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation and Pacemaker Implantation
Description: All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
Study: NCT04696237

Intervention type: OTHER
Intervention: Questionnaire
Description: a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed

Intervention type: OTHER
Intervention: Questionnaire
Description: a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
Study: NCT06371339

Intervention type: DEVICE
Group type: OTHER
Intervention: Additional acquisitions with the investigational gamma-camera  MoTI .
Description: The gamma-camera MoTI will be used for the study to carry out 3 or 4 additional acquisitions (depending on the therapeutic indication) compared with those provided for in standard practice with a conventional gamma camera (Syngula).~Patients will receive their treatment as usual in two stages:~* 1/ Pre-therapy phase:~  1. Administration of a tracer dose of 131I (Day 0).~ 2. Assessment of 131I uptake/fixation rate at Day 0, Day 1, Day 5.~ 3. Determination of the therapeutic dose of 131I to be administered to the patient after collegial discussion.~* 2/ Therapy phase:~  1. Administration of the therapeutic dose (Day 0).~ 2. Thyroid scintigraphy and measurement of the 131I uptake rate within 4 hours of treatment.~For the study, measurements of 131I uptake/fixation rates will be carried out using both the standard gamma camera Syngula and the gamma camera MoTI.
Study: NCT05259878

Intervention type: OTHER
Intervention: Adverse Childhood Events
Description: • The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood.
Study: NCT06446180

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SsK12@Lip@GSH
Description: SsK12@Lip@GSH powder contained no less than 5×10\^8 CFU viable cells of SsK12@Lip@GSH as the active ingredient.
Study: NCT05949671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean, gluten-free and mediterranean gluten-free diet intervention
Description: This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean, gluten-free and mediterranean gluten-free diet intervention
Description: This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean, gluten-free and mediterranean gluten-free diet intervention
Description: This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
Study: NCT06439121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-7-8 Breathing Technique
Description: Patients will be instructed to practice the 4-7-8 breathing technique once per hour (4 breaths) post-surgery. Pain and nausea-vomiting will be monitored at 0, 2, 6, 12, and 24 hours during their 24-hour hospital stay.
Study: NCT05160363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine Tetraphosphate
Description: A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyronaridine Tetraphosphate
Description: A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Piperaquine tetraphosphate
Description: A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine tetraphosphate
Description: A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
Study: NCT05298943

Intervention type: OTHER
Group type: OTHER
Intervention: walking in 4 situations
Description: Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
Study: NCT05624983

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: acoustic otoemisions
Description: TOAE and DPOAE

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: acoustic otoemisions
Description: TOAE and DPOAE

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Otoscopy
Description: presence of earwax checked by video otoscop

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Otoscopy
Description: presence of earwax checked by video otoscop

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Audiometry
Description: Hearing Threshold will be measured with the AD528 interacoustics

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Audiometry
Description: Hearing Threshold will be measured with the AD528 interacoustics

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tympanometry
Description: Tympanic mobility will be measyred with the Titan interacoustics

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tympanometry
Description: Tympanic mobility will be measyred with the Titan interacoustics
Study: NCT03258853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
Study: NCT05815680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
Study: NCT03258853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
Study: NCT05815680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
Study: NCT06026020

Intervention type: OTHER
Intervention: Biological samples collection
Description: Samples of blood, faeces, saliva are collected for analysis.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Samples of blood, faeces, saliva are collected for analysis.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Samples of blood, faeces, saliva are collected for analysis.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Samples of blood, faeces, saliva are collected for analysis.
Study: NCT05567484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered